Thanks, and welcome to the BrainStorm Cell Therapeutics second quarter 2025 conference call. At this time, all participants are in a listen-only mode. As a reminder, this call is being recorded. I would now like to introduce your host for today's call, Michael Wood of LifeSci Advisors. Mr. Wood, you may begin.
Thank you, Kelly. Good morning, everyone, and thank you for joining us this morning. Before passing it off to company management for prepared remarks, I would like to remind listeners that this conference call will contain numerous statements, descriptions, forecasts, and projections regarding BrainStorm Cell Therapeutics and its potential future business operations and performance, statements regarding the market potential for the treatment of neurodegenerative disorders such as ALS, the sufficiency of the company's existing capital resources for continuing operations in 2025 and beyond, the safety and clinical effectiveness of the NurOwn technology platform, clinical trials of NurOwn and related clinical development programs, and the company's ability to develop strategic collaborations and partnerships to support its business planning efforts. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond BrainStorm's control, including the risks and uncertainties described from time to time in the company's SEC filings. The company's results may differ materially from those projected on today's call, and the company undertakes no obligation to publicly update any forward-looking statements. Joining us on the call this morning will be Chaim Lebovits, President and CEO of BrainStorm, Dr. Bob Dagher, Executive Vice President and Chief Medical Officer, Haro Hartounian, Executive Vice President and Chief Operating Officer, and Alla Patlis, Interim Chief Financial Officer. I would now like to turn the call over to Mr. Lebovits. Please go ahead.
Thank you, Mike. Good morning, everyone. Thank you for joining us today.